Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADDXF NASDAQ:AZRX NASDAQ:LIXT OTCMKTS:NWPHF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/AAZRXAzurRx BioPharma$2.08-3.7%$4.04$3.36▼$26.30$19.40M1.51628,703 shs126,966 shsLIXTLixte Biotechnology$6.70-8.2%$5.40$0.68▼$7.78$100.86M1.27122,879 shs177,300 shsNWPHFNewron Pharmaceuticals$20.00$20.00$9.10▼$20.00$357M0.53600 shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%AZRXAzurRx BioPharma0.00%0.00%0.00%+2.46%+291.71%LIXTLixte Biotechnology-2.41%+6.10%+24.15%+144.15%+826.87%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%+113.68%+113.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/AAZRXAzurRx BioPharma$2.08-3.7%$4.04$3.36▼$26.30$19.40M1.51628,703 shs126,966 shsLIXTLixte Biotechnology$6.70-8.2%$5.40$0.68▼$7.78$100.86M1.27122,879 shs177,300 shsNWPHFNewron Pharmaceuticals$20.00$20.00$9.10▼$20.00$357M0.53600 shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%AZRXAzurRx BioPharma0.00%0.00%0.00%+2.46%+291.71%LIXTLixte Biotechnology-2.41%+6.10%+24.15%+144.15%+826.87%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%+113.68%+113.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADDXFAddex Therapeutics 0.00N/AN/AN/AAZRXAzurRx BioPharma 0.00N/AN/AN/ALIXTLixte Biotechnology 1.00SellN/AN/ANWPHFNewron Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LIXT, AZRX, ADDXF, and NWPHF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/A($0.76) per shareN/ALIXTLixte BiotechnologyN/AN/AN/AN/A$1.05 per shareN/ANWPHFNewron Pharmaceuticals$6.82M52.35N/AN/A$0.21 per share95.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AN/AAZRXAzurRx BioPharma-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/ALIXTLixte Biotechnology-$6.01M-$1.13N/AN/AN/AN/A-134.91%-95.61%N/ANWPHFNewron Pharmaceuticals-$17.63MN/AN/AN/AN/AN/AN/AN/AN/ALatest LIXT, AZRX, ADDXF, and NWPHF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LIXTLixte BiotechnologyN/A-$0.18N/A-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADDXFAddex TherapeuticsN/AN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ANWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADDXFAddex TherapeuticsN/AN/AN/AAZRXAzurRx BioPharmaN/A1.331.33LIXTLixte BiotechnologyN/A2.782.78NWPHFNewron PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADDXFAddex TherapeuticsN/AAZRXAzurRx BioPharma6.27%LIXTLixte Biotechnology5.10%NWPHFNewron PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADDXFAddex TherapeuticsN/AAZRXAzurRx BioPharma7.30%LIXTLixte Biotechnology9.50%NWPHFNewron PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADDXFAddex Therapeutics26N/AN/ANot OptionableAZRXAzurRx BioPharma129.33 million8.65 millionNot OptionableLIXTLixte Biotechnology415.02 million13.59 millionNot OptionableNWPHFNewron Pharmaceuticals2217.85 millionN/ANot OptionableLIXT, AZRX, ADDXF, and NWPHF HeadlinesRecent News About These CompaniesNewron Pharmaceuticals to Participate in June Investor ConferencesMay 28, 2026 | businesswire.comNewron announces US FDA has placed a hold on enrollment of new patients in US sites of its ENIGMA-TRS 2 study of evenamideMay 2, 2026 | pharmabiz.comPPatient death prompts FDA pause on Newron’s Phase 3 schizophrenia studyApril 30, 2026 | biospace.comBPatient death puts Newron’s late-stage schizophrenia trial on iceApril 30, 2026 | yahoo.comNewron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 StudyApril 29, 2026 | finance.yahoo.comFDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient deathApril 29, 2026 | fiercebiotech.comFNewron Announces AGM 2026 ResultsApril 23, 2026 | finance.yahoo.comNewron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Just Slashed This Year's EstimatesMarch 29, 2026 | finance.yahoo.comNewron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMarch 27, 2026 | finance.yahoo.comNewron Pharmaceuticals S.p.A. (NWPHF) Q4 2025 Earnings Call TranscriptMarch 24, 2026 | seekingalpha.comEQS-News: Newron presents 2025 financial results and provides 2026 outlookMarch 24, 2026 | sharewise.comSNewron Presents 2025 Financial Results and Provides 2026 OutlookMarch 24, 2026 | finance.yahoo.comNewron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)March 20, 2026 | businesswire.comNewron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance ContractMarch 19, 2026 | pharmiweb.comPNewron Announces Nominations to Its Board of Directors at Upcoming Annual General MeetingMarch 18, 2026 | tmcnet.comNewron Secures Funding to Advance Key Schizophrenia DrugMarch 17, 2026 | newscase.comNNewron secures up to EUR 38 million to advance its ENIGMA-TRS pivotal phase III programmeFebruary 18, 2026 | pharmabiz.comPNewron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug EvenamideFebruary 17, 2026 | theglobeandmail.comNewron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia DrugFebruary 17, 2026 | theglobeandmail.comNewron secures up to 38 million euros to advance evenamide programFebruary 17, 2026 | thepharmaletter.comTMedia Sentiment Over TimeLIXT, AZRX, ADDXF, and NWPHF Company DescriptionsAddex Therapeutics OTCMKTS:ADDXF$0.99 0.00 (0.00%) As of 02/3/2023Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.AzurRx BioPharma NASDAQ:AZRXAzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.Lixte Biotechnology NASDAQ:LIXT$6.70 -0.60 (-8.22%) As of 12:27 PM Eastern This is a fair market value price provided by Massive. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Newron Pharmaceuticals OTCMKTS:NWPHF$20.00 0.00 (0.00%) As of 06/23/2026Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning Why nVent Could Be a Long-Term AI Infrastructure Winner These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Chevron’s Microsoft Deal Turns Natural Gas Into an AI Trade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
